看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。4 y8 |' ]- @$ W" D6 ^" N& {
/ D4 v1 p! S9 w* x3 p( v. j- d! z, m% C; ^ x( F' H5 K
Currently available feasibility data for possible combination strategies.
) D. n: N) P3 k9 S+ k7 Q- R————————————————————————————————
( _, v; F% H* R( l% wCombination Feasibility according to preliminary data 4 F( N. m$ Y" J
——————————————————————————————————$ {8 n% o1 H, ]
Bevacizumab + sorafenib Yes, reduced dose
, q" X' n' e; X7 U; f' t1 kBevacizumab + sunitinib† No
9 z# I/ \7 B: d; ^Bevacizumab + temsirolimus Yes 3 I% |2 f& d; q* }) z
Bevacizumab + everolimus Yes
( }8 ^% p1 |5 }% t+ b/ r9 S+ @Sorafenib + sunitinib ?
1 {0 Z+ F* e# cSorafenib + temsirolimus Yes, reduced dose , p3 D( _% K* z% Z+ |
Sorafenib + everolimus Yes, reduced dose + u8 E6 ?3 X0 M K8 a! ^3 t) M* J
Sunitinib + temsirolimus† No 8 @# y. i. u& Y$ G: v1 I- A
Sunitinib + everolimus ? ( ?2 R$ z2 L5 b( i* @8 F
Temsirolimus + everolimus ?
! m. Z; p( T! {: L' J————————————————————
8 S- { M0 [* u: \†Led to US FDA warning.
]+ O2 X- b. }/ b- _1 h- Y I( f2 @?: As yet unattempted combination.
# W& f# U, l5 W |